Semaglutide has strong evidence for weight loss, type 2 diabetes, and heart health, while berberine has shown modest improvements in blood sugar and cholesterol
The protocol, dose, and frequency are individualized based on the patients cognitive goals and baseline
Certain profiles warrant more careful monitoring: Patients with existing diabetic retinopathy, particularly those with a history of poor blood sugar control Patients who have been diagnosed with or are at risk for age-related macular degeneration Those with hypertension, high cholesterol, or obstructive sleep apnea Patients with a small cup-to-disc ratio, which can only be assessed during a dilated eye exam Those starting semaglutide specifically, given its stronger association with both NAION and diabetic retinopathy compared to tirzepatide Knowing your individual risk profile before starting therapy, not after a vision change occurs, is the most effective approach
These effects are mediated through GLP-1 receptors (GLP-1R), which are widely distributed throughout the body, including the pancreas, liver, skeletal muscle, gastrointestinal tract, cardiovascular system, and central nervous system